MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 7,328 Shares of IDEXX Laboratories, Inc. $IDXX

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 67,215 shares of the company’s stock after purchasing an additional 7,328 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in IDEXX Laboratories were worth $28,227,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IDXX. Balyasny Asset Management L.P. grew its stake in shares of IDEXX Laboratories by 230.4% in the fourth quarter. Balyasny Asset Management L.P. now owns 2,455 shares of the company’s stock worth $1,015,000 after acquiring an additional 1,712 shares during the last quarter. Captrust Financial Advisors raised its position in shares of IDEXX Laboratories by 22.7% during the fourth quarter. Captrust Financial Advisors now owns 5,825 shares of the company’s stock valued at $2,408,000 after buying an additional 1,078 shares during the last quarter. Colonial Trust Co SC lifted its stake in shares of IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock valued at $35,000 after buying an additional 39 shares during the period. Deutsche Bank AG grew its position in IDEXX Laboratories by 17.9% during the fourth quarter. Deutsche Bank AG now owns 357,479 shares of the company’s stock worth $147,796,000 after buying an additional 54,360 shares in the last quarter. Finally, Focus Partners Wealth increased its stake in IDEXX Laboratories by 175.2% during the fourth quarter. Focus Partners Wealth now owns 40,576 shares of the company’s stock valued at $17,603,000 after acquiring an additional 25,830 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $642.99 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The firm has a market cap of $51.44 billion, a PE ratio of 53.54, a price-to-earnings-growth ratio of 4.16 and a beta of 1.56. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12. The company’s 50-day moving average price is $593.22 and its two-hundred day moving average price is $507.11.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the company posted $2.44 earnings per share. IDEXX Laboratories’s quarterly revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent research reports. Piper Sandler reissued a “neutral” rating and set a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Leerink Partners lifted their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Jefferies Financial Group initiated coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price target for the company. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a research note on Friday, August 15th. Finally, Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $649.44.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 2,187 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director directly owned 262 shares in the company, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael G. Erickson sold 406 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the transaction, the executive vice president owned 11,287 shares in the company, valued at approximately $7,336,098.52. This represents a 3.47% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,057 shares of company stock worth $34,293,468. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.